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More than 70 drugs present on the Swiss mar-
ket can cause drug-induced long QT syndrome
(LQTS), which is associated with torsades de
pointes (TdP) arrhythmias, potentially leading to
sudden cardiac death. Basic and clinical investiga-
tions performed during the last decade have helped
a better understanding of the mechanisms and risk
factors of this serious public health problem. In
their vast majority, QT interval prolonging drugs
block the human ERG (hERG) channel involved
in the repolarisation phase of the cardiac action po-
tential, and thus lengthen the QT interval. Beside
the well-known QT interval prolonging action of
class IA, IC and III anti-arrhythmic drugs, many
antibiotics, neurotropic, antifungal, and anti-
malarial drugs are also able to cause drug-induced
LQTS. Reviewing the literature indicates that the
risk of QT interval prolongation and TdP is in-
creased in females, in patients with organic heart
diseases and hypokalaemia. Furthermore in a few
cases, genetic factors have also been reported.
However thus far, no genetic test is available to 
detect at-risk patients, and in consequence, drug
prescribers are still relying only on the clinical his-
tory and findings to perform an evaluation of the
risk. Treatment of drug-induced LQTS and TdP
includes identifying and withdrawing the culprit
drug(s), infusing magnesium and, in resistant cases
acceleration of the heart rate. In this review article
we provide a list of QT interval prolonging drugs
adapted to the pharmaceuticals found on the Swiss
market that can be used as a check-list for drug pre-
scribers and at-risk patients.
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The long QT syndrome (LQTS) is charac-
terised by a prolonged QT interval in the surface
ECG, as well as a propensity to developing syn-
cope and sudden cardiac death (SCD). In most
documented cases, death was caused by the malig-
nant polymorphic ventricular arrhythmia called
torsades de pointes (TdP). Congenital and ac-
quired forms of LQTS are known. Administration
of drugs is one of the most frequent causes of ac-
quired LQTS [1–3]. Drug-induced long QT syn-
drome can, therefore, be defined as an “iatrogenic”
form of this potentially lethal condition. Cardiol-
ogists are familiar with this adverse drug effect be-
cause it has long been a well-known complication
of anti-arrhythmic drug treatment [4]. However,
since the nineties, it appeared that a large number
of non-anti-arrhythmic drugs may prolong the
QT interval and consequently predispose exposed
patients to TdP and lethal events [5]. Neverthe-
less, the occurrence of drug-induced TdP is infre-
quent, and the odds of a given patient on a QT in-
terval prolonging drug developing TdP are fortu-
nately small [6]. However, in terms of public health
and safety, due to the large number of patients re-
ceiving such drugs, this issue is becoming increas-
ingly important in daily clinical practice.
Figure 1 presents the number of cases of pro-
longed QT interval and/or TdP voluntarily re-
ported by health professionals to the Centre for
Pharmacovigilance of the Swiss agency of thera-
peutic products (Swissmedic) since 1997. The ab-
solute number of cases is small, and is probably af-
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fected by an underreporting bias. However, a trend
toward more cases being reported can be observed,
which might be due to a recent increase in aware-
ness of this topic. It is interesting to note that many
of the cases reported in 2002 and 2003 were related
to the use of methadone [7].
The aim of this review is twofold. First, we
present recent findings resulting from basic and
clinical investigations, since this field has been very
productive in the last 5 years. Indeed, significant
progress has been made in our understanding of
the molecular mechanisms underlying the delay in
cardiac repolarisation, and consequently QT in-
terval prolongation. Second, we also provide a list
of drugs known to prolong the QT interval and
that is adapted to the Swiss list of registered prod-
ucts. This list may be used as a check-list for drug
prescribers and given to patients at-risk of devel-
oping TdP, such as congenital LQTS patients.
Ionic and molecular determinants of cardiac ventricular repolarisation
The QT interval of the ECG is predominantly
determined by the duration of the action potential
(AP) of ventricular cells. Indeed, most cases of QT
interval prolongation are caused by factors that
prolong the duration of the AP, mainly by delay-
ing the repolarisation phase 3 as schematised in 
figure 2. A large number of recent studies allowed
the dissection of the individual contribution of
many different ionic currents, related ion trans-
porters and channels, to the generation of the AP
(fig. 3) [8]. Interestingly, the role of specific ion
channels in human physiology could only be ascer-
tained by the finding that alterations (ie, muta-
tions) of their genes caused congenital LQTS [9]. 
More than 20 currents subdivided into depo-
larising and repolarising currents are involved in
the AP generation of ventricular cells as illustrated
in Fig. 3. Depolarising currents are due to an “in-
ward” flux of positive charges (Na+ and Ca2+) into
the cells, and consequently they move the negative
resting membrane potential toward more positive
voltage values. Repolarisation is achieved by a de-
layed “outward” flux of positive charges (K+) out of
the cells. The particularity of the cardiac AP, as
compared to neuronal AP, is the “plateau” phase 2
which is mainly due to the inward flux of Ca2+ sig-
nificantly prolonging the AP duration (about
200–300 ms). More than 50 years ago the Swiss
physiologist S. Weidmann reported that the ab-
solute amount of current flowing through the
membrane of cardiac cells during the phase 2 is
very small [10]. As a result, small variations of
either depolarising or repolarising currents,
mainly during phase 2, can significantly alter the
AP duration [11]. The class III antiarrhythmic
drug sotalol potently blocks one of these outward
K+ currents (called IKr) [12], thus reducing the
repolarising current and consequently prolonging
both the AP and the QT interval. Sotalol has been
found to prolong the QT interval and cause TdP
in numerous clinical studies [13].
The congenital forms of the LQTS are caused
by mutations mostly located in genes encoding
cardiac ion channel subunits [14]. This disorder
therefore belongs to the genetic cardiac channe-
lopathies. In its classic description, the congenital
LQTS includes the Romano-Ward [15, 16] and
Jervell and Lange-Nielsen syndromes [17]. The
latter syndrome is also clinically characterised by
neurosensorial deafness. In the Romano-Ward
syndrome, patients have been found to be het-
erozygous carriers of mutations in the genes
KCNQ1, KCNH2, SCN5A, ANK2, KCNE1 and
KCNE2, defining respectively the LQT1 to LQT6
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Figure 1
Frequency of drug-
induced TdP and pro-
longed QT interval
voluntarily reported
to the Centre for
Pharmacovigilance of
Swissmedic per year.
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Scheme illustrating
the timing and the
chronological rela-
tionship of the car-
diac action potential
at the level of the
cardiac myocyte (A)
and the surface ECG
(B). The upstroke
depolarisation (0) is
rapidly followed by
an early repolarisa-
tion phase (1). The
plateau phase (2) is
long in ventricular
cells, and is followed
by the repolarisation
phase (3). Delayed
repolarisation (red)
may be caused by
either increased de-
polarising currents or
decreased repolaris-
ing currents. A pro-
longation of the ac-
tion potential dura-
tion causes a length-
ening of the QT inter-
val on the surface
ECG (red). See the
text for details.
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subtypes. For the Jervell and Lange-Nielsen syn-
drome, the JLN1 and 2 subtypes are caused by 
mutations of the KCNQ1 and KCNE1 genes; the
patients are homozygous carriers [18]. The alter-
ations caused by these mutations, in most cases,
prolong the AP duration by either increasing in-
ward/depolarising currents or decreasing out-
ward/repolarising currents during the plateau
phase. Most mutations found in the gene coding
for the cardiac voltage-gated sodium channel
Nav1.5, SCN5A, result in a small but clinically rel-
evant persistent depolarising current throughout
the AP duration. These mutations are referred 
as to “gain-of-function” alterations causing the
LQTS type-3 phenotype. Furthermore, numer-
ous mutations in five different genes encoding
channel subunits involved in the IKr, IKs and IK1
currents were also found in congenital LQTS. In
almost every case, these mutations, by different
mechanisms, reduce the outward repolarising cur-
rents (“loss-of-function” mutations), and conse-
quently prolong the AP duration and QT interval.
A significant proportion of the mutations causing
congenital LQTS is found in the gene KCNH2 en-
coding the K+ channel hERG (human Ether-à-go-
go Related Gene). In fact, almost all drugs known
to prolong the QT interval block the hERG chan-
nel, illustrating that congenital and drug-induced
forms of LQTS share similar pathogenic mecha-
nisms [19]. For further information, the website
“Inherited Arrhythmias Database” supported by
the European Society of Cardiology hosts an up-
dated list of published genes and mutations caus-
ing LQTS [20].
In summary, the AP duration of the ventricu-
lar cells is a major determinant of the QT interval.
Genetic or acquired factors that alter the delicate
balance between inward and outward currents dur-
ing the phase 2 of the AP significantly prolong its
duration, and consequently create a substrate for
TdP. The mechanism by which a prolonged AP
leads to TdP is still a matter of controversy [21,
22], and its discussion is beyond the scope of this
review.
Currents
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ITo2 (Ca2+ activated)
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Kv4.3
–
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Figure 3
Schematic representation of the ionic currents and ion transporters responsible for
the different phases of the cardiac action potential (AP). Red (depolarising) and blue
(repolarising) shapes are indicative for relative current amplitude, duration and direc-
tion. The shape of the current is aligned with its approximated time of action during
the AP. The phase 0 (upstroke depolarisation) is caused by the very rapid activation 
of voltage-gated sodium channels Nav1.5. These channels will afterwards inactivate
rapidly. The first repolarisation phase 1 (notch) is due to the transient outward
K+ current for which two components are recognised, Ito1 and Ito2. The plateau phase 2
is mainly maintained by inward Ca2+ current flowing through Cav1.2 voltage-gated
channels that inactivate slowly. Repolarisation (phase 3) is obtained through the con-
certed action of three types of outward currents called IKs (slow), IKr (rapid) and fi-
nally IK1. The main pore forming subunit (alpha subunits) of IKs is called KvLQT1 or
KCNQ1 (new nomenclature Kv7.1), of IKr hERG (new nomenclature Kv11.1) and for 
IK1 Kir2.1. These principal alpha subunits are often found in association with so-called
ancillary beta-subunits that are not directly involved in the gating machinery of the
channels. The currents generated by all other electrogenic transporters (ATPases, 
exchangers and ion channels) also contribute to shape the AP.
Normal values of QT interval
The QT interval is measured from the onset
of the QRS complex to the end of the T wave (Fig.
2B). Small physiological U waves should not be in-
cluded in the QT interval measurements. How-
ever, tall U waves that are not separated from the
T wave are considered pathological and may be
counted as part of the QT interval. The QT inter-
val adapts to the heart rate, the higher the rate, the
shorter the QT interval. It is therefore accepted to
normalise the QT interval for the heart rate. De-
spite several limitations, the most frequently used
formula to correct the QT interval value (QTc) for
the heart rate is the Bazett formula, where QTc =
QT/(RR)1/2 [23], RR is the preceding RR duration
expressed in seconds; this makes QTc equal to QT
for a heart rate of 60 bpm. For yet unknown rea-
sons, adult females have on average a QTc interval
about 20 ms longer than adult males, and in con-
sequence one has to refer to different normal val-
ues for both genders [24]. Table 1 presents QTc
values (corrected with the Bazett formula) that are
considered normal, borderline and clearly pro-
longed for both genders [25].
Adult Males Adult Females
Normal <430 ms <450 ms
Borderline 431–450 451–470
Prolonged >450 >470
Table 1
Corrected QT interval
values according to
the Committee for
Proprietary Medicinal
Products [25]; QTc 
according to Bazett
formula: QTc =
QT/(RR)1/2 [23].
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Recently, a novel and important concept has
been proposed: every individual seems to have a
physiological “cardiac repolarisation reserve”.
This functional reserve allows to counterbalance
any endogenous (genetic defects or cardiac disor-
ders for instance) or exogenous (drugs for exam-
ple) factors that would either reduce repolarising
or increase depolarising currents during the AP
[26]. The extent of this cardiac repolarisation 
reserve is variable, and may be reduced in some 
individuals. It can therefore be postulated that in-
dividuals with a reduced repolarisation reserve are
more susceptible to developing significant and
manifest QT interval prolongation and TdP when
exposed to IKr blocking drugs. As stated above,
women tend to have a longer QT interval, most
probably because their cardiac cells generate less
repolarising current [27]. The reduced repolarisa-
tion reserve in women may explain their increased
propensity to develop TdP when taking QT inter-
val prolonging drugs [28]. It has also been sug-
gested that the magnitude of this repolarisation 
reserve is genetically determined [29, 30]. Asymp-
tomatic individuals with normal or “borderline”
ECGs at baseline, may harbour genetic variants re-
ducing their cardiac repolarising currents, corre-
sponding to a “forme fruste” of LQTS [31]. Sev-
eral case reports were recently published clearly
supporting this concept [32–34]. In these cases, pa-
tients with a normal baseline ECG, but manifest
QT interval prolongation when taking an IKr
blocking drug, were found to have mutations in the
same genes (cardiac ion channel subunits) as in
congenital LQTS patients [30]. 
Cardiac repolarisation reserve
Acquired forms of long QT syndromes
Beside the congenital forms of LQTS, pro-
longed QT interval is also observed in many dif-
ferent acquired clinical conditions presented in
table 2. The role of drugs in causing LQTS is
clearly important and clinically relevant since it
can be prevented in many circumstances. Cardiac
disorders are also a frequent cause of acquired
LQTS. QT interval prolongation has been re-
ported in chronic heart failure [35, 36], acute and
chronic ischaemic heart disease [37–39], and car-
diomyopathies [40]. Bradycardia due to sinus dys-
function, as well as conduction block, has also been
shown to prolong the QT interval [41–43]. Elec-
trolyte imbalance, mainly hypokalaemia, hypo-
magnesaemia and hypocalcaemia, is also a com-
mon cause of prolonged QT interval. Interest-
ingly, it appears that a low plasma/extracellular K+
concentration prolongs the AP by reducing the
hERG mediated IKr currents in experimental set-
tings. The molecular mechanism of this apparent
paradoxical phenomenon has been recently unrav-
elled [44]. Here again, the channel hERG plays a
central role in this delayed repolarisation disorder.
Finally many metabolic, nutritional, neurological
and endocrine pathological conditions have been
reported to prolong the QT interval (table 2).
Long QT syndromes: congenital forms
Romano-Ward Syndrome: LQT1–LQT6
Jervell and Lange-Nielsen Syndrome: J-LN1 and J-LN2
Associated with the Andersen Syndrome: AND1 or LQT-7
Associated with Syndactyly
Long QT syndromes: acquired forms
Antiarrhythmic drugs (IA, IC and III)
Other drugs (antibiotics, antifungal, psychotropic drugs, …)
Cardiac disorders (chronic heart failure, cardiomyopathies, …)
Electrolyte disorders: hypokalemia, hypocalcemia 
and hypomagnesemia
Neurological disorders
Nutritional (alcoholism, anorexia, …)
other
Table 2
Congenital and ac-
quired forms of long
QT syndromes. Muta-
tions in six different
genes have been
identified in patients
and families with
congenital LQTS, al-
lowing the classifica-
tion of LQT1–LQT6.
The Andersen syn-
drome (AND1 or
LQT7) is a rare dis-
order characterised
by neurological and
morphological abnor-
malities in addition
to a prolonged QT
interval [62]. Three
sporadic cases of
prolonged QT inter-
val associated with
syndactyly have been
reported [63]. How-
ever, the significance
of this finding may
be quite low because
of its rarity.
Drug-induced long QT syndrome
Molecular and structural aspects of 
drug-induced long QT syndrome
With only a few exceptions (see [3, 45] for an
extensive discussion), all different drugs known to
prolong the QT interval were shown either to
block the hERG channels or to reduce the IKr cur-
rent recorded in cardiac myocytes. This observa-
tion has been quite puzzling since, unlike other ion
channels, the chemical structures of these hERG-
blocking drugs are very diverse. However, with
class Ic drugs, such as flecainide, the QT interval
prolongation is mainly caused by an increase in
QRS duration due to a blockade of sodium chan-
nels. Inhibition of hERG channels by flecainide
[46] is most likely marginal since the JT interval is
not significantly increased in humans [47]. Fur-
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thermore, flecainide has been recently shown to
decrease the QT interval in patients with Nav1.5
gene mutations [48, 49].
The human ERG (kv11.1) channel gene
KCNH2 was cloned in 1994 [50], and not long after
was shown to be mutated in patients suffering from
the congenital LQTS type-2 [51]. Simultaneously,
it was found to be the target of many drugs pro-
longing the QT interval [52]. These findings
clearly underscored the pivotal role of the encoded
channel in normal as well abnormal cardiac ex-
citability. The currents mediated by the hERG
potassium channel, when studied in expression
systems, recapitulate most of the key characteris-
tics of the IKr currents found in human cardiac
myocytes, namely a rapidly activating outward
voltage-gated potassium current, with strong in-
ward rectification properties [51]. As illustrated in
Fig. 4, the native channels are formed by tetramers
of four identical subunits (alpha-subunits), each
consisting of six transmembrane domains, with the
S4 segment serving as the main voltage sensor
thanks to its positively charged amino acids. 
Recent structural studies provided interesting
elements of response to the question of why so
many drugs can bind to and block hERG channels
[53–55]. Two main features were found to be im-
portant. First, most K+ channels – but not hERG
– have two proline residues in the last transmem-
brane segment (S6) of the alpha-subunit, that pro-
duce a sharp bend in the four S6 helices, thus re-
ducing the volume of the cavity inside the channel.
Hence, the hERG channel lacks this kink and the
larger inner pore volume can accommodate larger
chemical structures than in other K+ channels. Sec-
ond, two aromatic residues (tyrosine and pheny-
lalanine) face the central cavity of the channel (fig.
4) allowing high affinity Pi-stacking interactions
with aromatic moieties found in the blocking
drugs. Detailed mutational studies clearly support
this structural model [53, 54], and provide a ration-
ale for the development of future drugs that may
not interact with hERG channels.
Risk factors for developing TdP
The occurrence of TdP in patients taking non-
antiarrhythmic drugs is defined as an idiosyncratic
reaction. Indeed, it represents an adverse drug re-
action that is infrequently encountered (see fig. 1)
and not predictable at the present time. However,
during the last few years several systematic studies
have aimed at better defining the risk factors for
developing QT interval prolongation and TdP 
in patients. These clinical factors were recently
analysed in an extensive review of the literature
[56] (table 3). In this work, Zeltser et al. identified
249 reported patients with TdP related to the use
of non-cardiac drugs [56]. As previously reported
[30] and discussed [57], the most commonly iden-
tified risk factor was female gender (71% of all 
patients). Heart diseases and hypokalaemia were
respectively reported in 41% and 28% of patients.
Importantly, potential drug interactions associated
with the administration of two or more drugs 
prolonging the QT interval were present in 39%
of patients. However, only 18% of all patients with
drug-induced TdP had a familial history of LQTS,
a previous episode of TdP or an obviously pro-
longed QT interval in the absence of drug [56].
Less commonly identified risk factors were brady-
cardia and diuretic treatment.
Practical attitudes – prevention
Despite the low prevalence of drug-induced
TdP in the general population, the risk can be fur-
ther reduced by carefully obtaining the patient’s
medical history. Viskin et al. recently provided
practical approaches for risk stratification [58] in
patients taking non-antiarrhythmic drugs that can
potentially prolong the QT interval. As presented
in Table 4, the risk may be classified from “very
low” in patients without risk factors (Table 3), to
Figure 4
Molecular structure
and membrane topol-
ogy of the hERG
(Kv11.1) channel. 
(A) The molecular 
architecture of hERG
is similar to that of
other voltage-gated
K+ channels. Four
alpha subunits co-as-
semble to form the
full hERG channel.
Each alpha subunit
has six transmem-
brane domains, intra-
cellular N- and C-ter-
mini and a pore loop
(P loop) linking the
S5 and S6 domains.
The S4 segment
contains positive
charges serving as
the voltage sensors.
In the alpha subunits
of the hERG channel,
the S6 segment con-
tains two aromatic
amino acids (tyro-
sine-Tyr and pheny-
lalanine-Phe), which
participate in the
binding site of most
of the drugs blocking
this channel (see text
for details). (B) Three
of the four alpha sub-
units of the hERG
channel are schema-
tised in this diagram.
The central cavity
lined by the four S6
segments is espe-
cially wide for this
channel because
these segments lack
a bend found in other
K+ channels. This pe-
culiarity may explain
why hERG channels
can be blocked by
drugs of many differ-
ent chemical struc-
tures.
hERG a subunit
outside
4
inside
A
B
Risk factors commonly identified
Female gender
Heart disease (cardiac hypertrophy, chronic heart failure, 
cardiomyopathies)
Hypokalemia, hypocalcemia and hypomagnesemia
High drug levels (impaired metabolism or excessive dosage)
Drug interactions (concomitant use of 2 drugs that prolong
the QT interval)
Risk factors less commonly identified 
Bradycardia
Diuretic use
History of congenital long QT syndrome
Prolonged baseline QT interval
Genetic variants (polymorphisms or mutations)
Table 3
Identified risk factors
for developing TdP in
patients taking drugs
that prolong the QT
interval. Modified
from Viskin S, Justo D,
Halkin A, Zeltser D.
Long QT syndrome
caused by non-cardiac
drugs. Progress in
Cardiovascular Dis-
eases 2003;45:415–27
[58], with permission
from Elsevier. 
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“very high” in patients with a history of drug-in-
duced or congenital LQTS. In high-risk patients,
administration of any drug known to prolong the
QT interval is contraindicated. In low-risk pa-
tients, the most important preventive measure is 
to carefully avoid administering more than one drug
known to prolong the QT interval. This is important
because many clinical situations exist where this
could occur: for instance, clarithromycin treat-
ment in a psychiatric patient under risperidone, or,
cisapride treatment in a patient treated with sotalol
for atrial fibrillation. It is also crucial to be aware
of drugs or food, such as grapefruit juice [59], that
inhibit the metabolism of drugs prolonging the
QT interval. For instance, drugs such as fluoxetine
and methadone (table 5) are both metabolised 
by the CYP34A enzymes that are inhibited by
macrolide antibiotics, antifungal drugs and grape-
fruit juice.
It has to be stated, however, that the recom-
mendations found in table 4 are, thus far, not sup-
ported by any kind of clinical trial.
Risk Definition Screening ECG Follow-Up ECG Cardiologist ECG Monitoring
Consultation
Very low No risk factors Not required Not required Not required Not required
are present
Low Women without Not required Not required Not required Not required
risk factors
Medium Heart disease Advisable Advisable Advisable Not required
High Drug interactions Required Required Required Questionable
Very high History of  LQTS Mandatory Mandatory Mandatory Mandatory
Table 4
Proposed practical
approaches when
prescribing non-an-
tiarrhythmic drugs
known to prolong 
the QT interval in pa-
tients. Hospitalisation
with ECG monitoring
is only mandatory 
in high risk patients
who need to be
treated with QT inter-
val prolonging drugs.
Modified from Viskin
S, Justo D, Halkin A,
Zeltser D. Long QT
syndrome caused by
non-cardiac drugs.
Progress in Cardio-
vascular Diseases
2003;45:415–27 [58],
with permission from
Elsevier. 
Drugs for cardiovascular disorders
Amiodarone Cordarone® Amiodarone-Mepha® Other
Disopyramide Norpace®
Dobutamine Dobutrex®
Dopamine Dopamin B. Braun
Ephedrine Ephedrin Streuli Demo® elixir Other
Epinephrine Adrenaline Sintetica EpiPen® Other
Flecainide Tambocor®
Ibutilide Corvert®
Indapamide Fludapamide® Fludex® SR Other
Isradipine Lomir SRO®
Midodrine Gutron®
Norepinephrine Scandonest Xylestesin® Other
Quinidine Kinidin-Duriles®
Sotalol Sotalex® Sotalol-Mepha®
Drugs for neuropsychiatric disorders
Amitriptyline Saroten® Retard Tryptizol® Limbitrol®
Chloral Hydrate Chloraldurat® Medianox® Nervifene®
Citalopram Citalopram-Mepha® Other
Chlorpromazine Chlorazin®
Clomipramine Anafranil®
Doxepine Sinquane®
Droperidol
Felbamate Taloxa®
Fluoxetine Fluctine® Fluocin® Other
Flupentixol Fluanxol® Deanxit®
Galantamine Reminyl®
Haloperidol Haldol® Sigaperidol®
Imipramine Tofranil®
Levomepromazine Nozinan®
Lithium Priadel® Neurolithium® Other
Methadone Ketalgine® Methadone Streuli
Methylphenidate Ritalin® Concerta®
Table 5
List of drugs found
on the Swiss market
that can prolong the
QT interval. 
The drugs found on
this list have been
shown to either block
the hERG channel or
to prolong the QT 
interval in humans.
This list is adapted
from the ACERT list
available on the
www.QTdrugs.org or
www.torsades.org
websites. It reflects
the last updated 
version of April 20th
2004, and will be
available as an up-
dated version on the
www.QTsyndrome.ch
website. At-risk 
patients (see Tables 3
and 4) should be 
informed that taking
these drugs is 
contraindicated or
should only be used
in exceptional 
circumstances such
as vital indications, 
if no safer alternative
is available. 
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Nortriptyline Nortrilen®
Olanzapine Zyprexa®
Paroxetine Deroxat® Parexat®
Quetiapine Seroquel®
Risperidone Risperdal®
Sertindole Serdolect®
Sertraline Zoloft® Gladem®
Thioridazine Melleril® Mellerettes®
Tizanidine Sirdalud®/- MR
Trimipramine Surmontil® Trimin®
Venlafaxine Efexor®
Drugs for gastrointestinal disorders
Cisapride Prepulsid®
Dolasetron Anzemet®
Domperidone Motilium®/-lingual
Granisetron Kytril®
Octreotide Sandostatine®
Ondansetron Zofran®
Phentermine Adipex® Ionamine®
Sibutramine Reductil® 10/15
Drugs for respiratory disorders
Salbutamol Ventolin® Ecovent® Other
Salmeterol Serevent® Seretide®
Terbutaline Bricanyl®
Drugs against bacterial infections
Azithromycine Zithromax®
Ciprofloxacine Ciproxine® Ciproflox® Other
Clarithromycine Klacid® Klaciped®
Erythromycine Erythrocine® Karex® Other
Levofloxacine Tavanic®
Moxifloxacine Avalox®
Ofloxacine Tarivid®
Trimethoprime- Bactrim® Cotrim® Other
Sulfamethoxazole
Drugs against viral infections
Amantadine Symmetrel® PK-Merz®
Foscarnet Foscavir®
Drugs against parasitic infections
Chloroquine Nivaquine® Chlorochin®
Mefloquine Lariam® Mephaquine® Other
Pentamidine Pentacarinat®
Drugs against fungal infections
Fluconazole Diflucan®
Itraconazole Sporanox®
Ketoconazole Nizoral®
Voriconazole Vfend®
Other drugs
Alfuzosin Xatral®
Phenylephrine Phenylephrine 5% Phenylephrine 5% SDU Faure Other
Phenylpropanolamine Kontexin® Retard Rhinotussal® Other
Pseudoephedrine Otrinol® Benical® Other
Tacrolimus Prograf® Protopic®
Tamoxifene Tamoxifen Farmos Novaldex® Other
Vardenafil Levitra®
Table 5 cont.
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Performing serial ECGs in patients receiving
one or several drugs known to prolong the QT 
interval is of questionable usefulness, since clinical
evidence is lacking to support definite recommen-
dations in this area. Drug-related ECG alterations
are fluctuating, and even in congenital LQTS pa-
tients ECG, may fail to show QT interval prolon-
gation. It would be exaggerated to suggest that the
prescription of any drug in table 5 imposes an 
ECG recording to all patients. On the other hand,
a new QT interval prolongation above 470 ms in
a patient taking such a drug, should lead to a de-
crease or cessation of the treatment. In patients at
risk, eg, those having already presented with QT
interval prolongation and who must receive a drug
with arrhythmic potential, or those receiving sev-
eral drugs from table 5 for life-saving indications,
ECG monitoring might be considered justified on
empirical grounds. But even in such selected cases,
the sensitivity and specificity of ECG tracings to
detect and prevent life-threatening arrhythmia has
not been established. Cardiology patients receiv-
ing antiarrhythmic drugs known to prolong the
QT interval should have a control ECG 4–6 days
after the initiation of the treatment.
Patients who definitely develop significant
prolongation of the QT interval (>30 ms as com-
pared to baseline [25]) or TdP after administration
of a QT interval prolonging drug should be in-
formed about their risk when re-exposed to simi-
lar drugs. We recommend carefully informing
such patients and providing them with the list
found in table 5 (see below). In addition, in
Switzerland suspected or confirmed drug-induced
TdP cases have to be reported to the Swiss-
medic pharmacovigilance office by filling in the
form found in the Swiss drug compendium or
downloaded from the Swissmedic website
(http://www.swissmedic.ch/files/formulare/B3.2.
16–d.pdf).
Practical attitudes – treatments
In an acute setting, the management of pa-
tients with drug-induced TdP should first aim at
identifying and discontinuing the QT interval pro-
longing drug(s), and maintain a plasma K+ concen-
tration between 4–4.5 mmol/L. Administration of
1–2 g magnesium sulphate i.v. reduces the occur-
rence of TdP [60]. Patients who are symptom-free
should receive slow injections (1–2 g over 2 min),
whereas, in patients with long runs of TdP, 2 g over
30–60 s may be administered. The 2 g dose can be
repeated once after 5–15 min, and followed by an
i.v. infusion of magnesium at a rate of 2 to 4 mg/
min. At higher doses, toxic effects such as hypoten-
sion, lethargy and eventually cardiac arrest may
occur [1]. In refractory patients, or those with fre-
quent pauses after ventricular premature beats,
heart rate acceleration by means of cardiac pacing
may be required since bradycardia increases the
risk of TdP initiation in the presence of prolonged
QT interval. 
A special case is represented by patients with
tachyarrhythmias in the setting of tricyclic antide-
pressant intoxication. Because of its concomitant
blocking effect of sodium and hERG channels, this
class of drug may lead to severe ventricular tachy-
cardias, which are difficult to treat. In patients with
acidosis, alkalinisation of the serum (and poten-
tially the urine) using sodium bicarbonate is the
treatment of choice [61].
List of QT interval prolonging drugs found
on the Swiss market
Patients at risk of developing TdP should ob-
viously avoid QT interval prolonging drugs. How-
ever, the list of such drugs is long and in some 
situations alternative treatments may be difficult 
to find, for instance tamoxifen treatment in breast
cancer patients. Several review articles and text-
books provide such lists, but none is adapted to the
drugs found on the Swiss market. We therefore
adapted the list maintained by the Arizona Center
for Education and Research on Therapeutics
(ACERT, www.QTdrugs.org or www.torsades.org,
last updated version of April 20th 2004) to the Swiss
drugs. To the best of our knowledge, this is the
most accurate and updated available list according
to new findings from the literature or the Federal
Drug Administration of the USA. Drugs not on
the Swiss market were removed and drugs not on
the US market were added (Table 5). We did not
subdivide the list into four classes as on the
ACERT site for the sake of simplicity. Interested
physicians are encouraged to visit this site for fur-
ther information. Of note, drugs that are not on
this list can not be considered as risk-free, since
many old compounds available on the market may
not have been investigated for their specific effects
on the QT interval or the hERG channels. This
document (table 5) may be given to the patients at-
risk, informing them that taking drugs found on
that list is contraindicated or should only be used
in exceptional circumstances such as vital indica-
tions, if no safer alternative is available. We plan to
keep an updated version of this Swiss list on the
www.QTsyndrome.ch website.
Conclusions
Prolongation of the QT interval in congenital
or acquired LQTS is associated with an increased
risk of TdP and SCD. By far, the most common
cause of acquired LQTS is drug-induced, the an-
tiarrhythmic drugs being the pharmaceutical class
most commonly implicated. However since the
nineties, the regulatory authorities had to remove
a significant number of non-cardiac drugs from the
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market because of their propensity to prolong the
QT interval and cause TdP. Recent basic and clin-
ical studies have allowed a better understanding of
the molecular determinants of this phenomenon
and its associated risk factors. Nevertheless, a key
question which is still awaiting an answer is why
the response of individual patients is so variable.
Genetic factors modulating the pharmacokinetics
and/or pharmacodynamics of these drugs are likely
to be involved. However thus far, only scant infor-
mation supporting this notion is available, and ge-
netic tests for the identification of patients at high
risk are not yet available. In most cases, clinicians
are therefore relying solely on clinical history and
findings in order to asses the risk before prescrib-
ing drugs. Furthermore, the list of offending drugs
is still growing (vardenafil being the most recently
added), and as a result, the risk of drug-induced
TdP will probably remain a significant issue in the
future. In order to minimise the risk of this serious
pro-arrhythmic effect, all health professionals pre-
scribing and/or dispensing drugs, as well as the
patients taking these drugs, have to be informed
about these risks and educated accordingly.
Note added in proof: Congenital LQTS associated
with syndactyly (table 2) has been recently shown to be
caused by mutations in the gene encoding the Cav1.2 cal-
cium channel. Reference: Splawski I, Timothy KW,
Sharpe LM, Decher N, Kumar P, et al. Ca(V)1.2 calcium
channel dysfunction causes a multisystem disorder includ-
ing arrhythmia and autism. Cell 2004;119:19–31.
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